Perseus Proteomics (TSE:4882) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Perseus Proteomics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Perseus Proteomics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Perseus Proteomics's Cash-to-Debt or its related term are showing as below:

TSE:4882' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 6 years, Perseus Proteomics's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

TSE:4882's Cash-to-Debt is ranked better than
99.71% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs TSE:4882: No Debt

Perseus Proteomics Cash-to-Debt Historical Data

The historical data trend for Perseus Proteomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Perseus Proteomics Cash-to-Debt Chart

Perseus Proteomics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Perseus Proteomics Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Perseus Proteomics's Cash-to-Debt

For the Drug Manufacturers - General subindustry, Perseus Proteomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perseus Proteomics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's Cash-to-Debt falls into.

Perseus Proteomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Perseus Proteomics's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Perseus Proteomics had no debt ⁽¹⁾.

Perseus Proteomics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Perseus Proteomics had no debt ⁽¹⁾.

Perseus Proteomics (TSE:4882) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Perseus Proteomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Perseus Proteomics (TSE:4882) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041

Website

https://www.ppmx.com

Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines

Perseus Proteomics (TSE:4882) Cash-to-Debt : No Debt (1) (As of Dec. 2023)